Daxor Corporation (DXR) Stock Competitors & Peer Comparison
See (DXR) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DXR | $9.58 | -5.15% | 51M | 6.18 | $1.64 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 21.44 | $2.76 | +2.46% |
| BDX | $150.09 | +0.07% | 55.1B | 26.52 | $5.73 | +2.46% |
| ALC | $67.07 | +1.45% | 33.1B | 40.66 | $1.67 | +0.53% |
| MDLN | $37.07 | +9.66% | 30.5B | 31.59 | $1.14 | N/A |
| WST | $330.31 | +3.30% | 23.6B | 44.66 | $7.49 | +0.26% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.46% |
| COO | $67.79 | +1.49% | 13.4B | 34.14 | $2.01 | N/A |
| BAX | $20.50 | +6.52% | 10.3B | -10.48 | -$1.91 | +1.00% |
Stock Comparison
DXR vs BDXA Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, DXR is priced at $9.58, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas BDXA's P/E ratio is 21.44. In terms of profitability, DXR's ROE is +0.22%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, DXR is more volatile compared to BDXA. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check BDXA's competition here
DXR vs BDX Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, BDX has a market cap of 55.1B. Regarding current trading prices, DXR is priced at $9.58, while BDX trades at $150.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas BDX's P/E ratio is 26.52. In terms of profitability, DXR's ROE is +0.22%, compared to BDX's ROE of +0.05%. Regarding short-term risk, DXR is more volatile compared to BDX. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check BDX's competition here
DXR vs ALC Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, ALC has a market cap of 33.1B. Regarding current trading prices, DXR is priced at $9.58, while ALC trades at $67.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas ALC's P/E ratio is 40.66. In terms of profitability, DXR's ROE is +0.22%, compared to ALC's ROE of +0.04%. Regarding short-term risk, DXR is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check ALC's competition here
DXR vs MDLN Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, MDLN has a market cap of 30.5B. Regarding current trading prices, DXR is priced at $9.58, while MDLN trades at $37.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas MDLN's P/E ratio is 31.59. In terms of profitability, DXR's ROE is +0.22%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, DXR is more volatile compared to MDLN. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check MDLN's competition here
DXR vs WST Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, WST has a market cap of 23.6B. Regarding current trading prices, DXR is priced at $9.58, while WST trades at $330.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas WST's P/E ratio is 44.66. In terms of profitability, DXR's ROE is +0.22%, compared to WST's ROE of +0.18%. Regarding short-term risk, DXR is more volatile compared to WST. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check WST's competition here
DXR vs HOLX Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, DXR is priced at $9.58, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas HOLX's P/E ratio is 31.54. In terms of profitability, DXR's ROE is +0.22%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, DXR is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check HOLX's competition here
DXR vs BDXB Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, DXR is priced at $9.58, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas BDXB's P/E ratio is 7.60. In terms of profitability, DXR's ROE is +0.22%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, DXR is more volatile compared to BDXB. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check BDXB's competition here
DXR vs COO Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, COO has a market cap of 13.4B. Regarding current trading prices, DXR is priced at $9.58, while COO trades at $67.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas COO's P/E ratio is 34.14. In terms of profitability, DXR's ROE is +0.22%, compared to COO's ROE of +0.03%. Regarding short-term risk, DXR is more volatile compared to COO. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check COO's competition here
DXR vs BAX Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, BAX has a market cap of 10.3B. Regarding current trading prices, DXR is priced at $9.58, while BAX trades at $20.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas BAX's P/E ratio is -10.48. In terms of profitability, DXR's ROE is +0.22%, compared to BAX's ROE of -0.16%. Regarding short-term risk, DXR is more volatile compared to BAX. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check BAX's competition here
DXR vs ATR Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, ATR has a market cap of 7.4B. Regarding current trading prices, DXR is priced at $9.58, while ATR trades at $115.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas ATR's P/E ratio is 19.83. In terms of profitability, DXR's ROE is +0.22%, compared to ATR's ROE of +0.14%. Regarding short-term risk, DXR is more volatile compared to ATR. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check ATR's competition here
DXR vs RGEN Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, RGEN has a market cap of 7.3B. Regarding current trading prices, DXR is priced at $9.58, while RGEN trades at $131.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas RGEN's P/E ratio is 143.00. In terms of profitability, DXR's ROE is +0.22%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, DXR is more volatile compared to RGEN. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check RGEN's competition here
DXR vs AVTR Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, AVTR has a market cap of 6.8B. Regarding current trading prices, DXR is priced at $9.58, while AVTR trades at $9.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas AVTR's P/E ratio is -12.24. In terms of profitability, DXR's ROE is +0.22%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, DXR is more volatile compared to AVTR. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check AVTR's competition here
DXR vs TFX Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, TFX has a market cap of 6B. Regarding current trading prices, DXR is priced at $9.58, while TFX trades at $135.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas TFX's P/E ratio is 1940.43. In terms of profitability, DXR's ROE is +0.22%, compared to TFX's ROE of -0.28%. Regarding short-term risk, DXR is more volatile compared to TFX. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check TFX's competition here
DXR vs BLCO Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, BLCO has a market cap of 5.6B. Regarding current trading prices, DXR is priced at $9.58, while BLCO trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas BLCO's P/E ratio is -25.25. In terms of profitability, DXR's ROE is +0.22%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, DXR is more volatile compared to BLCO. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check BLCO's competition here
DXR vs STVN Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, STVN has a market cap of 4.9B. Regarding current trading prices, DXR is priced at $9.58, while STVN trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas STVN's P/E ratio is 30.66. In terms of profitability, DXR's ROE is +0.22%, compared to STVN's ROE of +0.10%. Regarding short-term risk, DXR is more volatile compared to STVN. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check STVN's competition here
DXR vs MMSI Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, MMSI has a market cap of 4B. Regarding current trading prices, DXR is priced at $9.58, while MMSI trades at $67.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas MMSI's P/E ratio is 29.10. In terms of profitability, DXR's ROE is +0.22%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, DXR is more volatile compared to MMSI. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check MMSI's competition here
DXR vs HAE Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, HAE has a market cap of 3.6B. Regarding current trading prices, DXR is priced at $9.58, while HAE trades at $79.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas HAE's P/E ratio is 38.43. In terms of profitability, DXR's ROE is +0.22%, compared to HAE's ROE of +0.11%. Regarding short-term risk, DXR is more volatile compared to HAE. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check HAE's competition here
DXR vs ICUI Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, ICUI has a market cap of 3.5B. Regarding current trading prices, DXR is priced at $9.58, while ICUI trades at $142.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas ICUI's P/E ratio is 76.34. In terms of profitability, DXR's ROE is +0.22%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, DXR is more volatile compared to ICUI. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check ICUI's competition here
DXR vs WRBY Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, WRBY has a market cap of 3B. Regarding current trading prices, DXR is priced at $9.58, while WRBY trades at $25.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas WRBY's P/E ratio is 2485.00. In terms of profitability, DXR's ROE is +0.22%, compared to WRBY's ROE of +0.00%. Regarding short-term risk, DXR is more volatile compared to WRBY. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check WRBY's competition here
DXR vs LMAT Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, LMAT has a market cap of 2.2B. Regarding current trading prices, DXR is priced at $9.58, while LMAT trades at $96.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas LMAT's P/E ratio is 35.51. In terms of profitability, DXR's ROE is +0.22%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, DXR is more volatile compared to LMAT. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check LMAT's competition here
DXR vs XRAY Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, XRAY has a market cap of 2.1B. Regarding current trading prices, DXR is priced at $9.58, while XRAY trades at $10.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas XRAY's P/E ratio is -3.32. In terms of profitability, DXR's ROE is +0.22%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, DXR is more volatile compared to XRAY. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check XRAY's competition here
DXR vs NVCR Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, NVCR has a market cap of 2B. Regarding current trading prices, DXR is priced at $9.58, while NVCR trades at $16.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas NVCR's P/E ratio is -11.27. In terms of profitability, DXR's ROE is +0.22%, compared to NVCR's ROE of -0.51%. Regarding short-term risk, DXR is more volatile compared to NVCR. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check NVCR's competition here
DXR vs PLSE Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, PLSE has a market cap of 1.8B. Regarding current trading prices, DXR is priced at $9.58, while PLSE trades at $25.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas PLSE's P/E ratio is -23.43. In terms of profitability, DXR's ROE is +0.22%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, DXR is more volatile compared to PLSE. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check PLSE's competition here
DXR vs STAA Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, STAA has a market cap of 1.5B. Regarding current trading prices, DXR is priced at $9.58, while STAA trades at $29.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas STAA's P/E ratio is -71.12. In terms of profitability, DXR's ROE is +0.22%, compared to STAA's ROE of -0.06%. Regarding short-term risk, DXR is more volatile compared to STAA. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check STAA's competition here
DXR vs ATRC Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, ATRC has a market cap of 1.4B. Regarding current trading prices, DXR is priced at $9.58, while ATRC trades at $27.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas ATRC's P/E ratio is -273.00. In terms of profitability, DXR's ROE is +0.22%, compared to ATRC's ROE of -0.01%. Regarding short-term risk, DXR is more volatile compared to ATRC. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check ATRC's competition here
DXR vs BLFS Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, BLFS has a market cap of 1.3B. Regarding current trading prices, DXR is priced at $9.58, while BLFS trades at $27.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas BLFS's P/E ratio is -114.79. In terms of profitability, DXR's ROE is +0.22%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, DXR is more volatile compared to BLFS. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check BLFS's competition here
DXR vs KMTS Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, KMTS has a market cap of 1.2B. Regarding current trading prices, DXR is priced at $9.58, while KMTS trades at $19.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas KMTS's P/E ratio is -3.65. In terms of profitability, DXR's ROE is +0.22%, compared to KMTS's ROE of -0.69%. Regarding short-term risk, DXR is more volatile compared to KMTS. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check KMTS's competition here
DXR vs AZTA Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, AZTA has a market cap of 1B. Regarding current trading prices, DXR is priced at $9.58, while AZTA trades at $22.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas AZTA's P/E ratio is -9.43. In terms of profitability, DXR's ROE is +0.22%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, DXR is more volatile compared to AZTA. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check AZTA's competition here
DXR vs QDEL Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, QDEL has a market cap of 950.6M. Regarding current trading prices, DXR is priced at $9.58, while QDEL trades at $13.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas QDEL's P/E ratio is -0.78. In terms of profitability, DXR's ROE is +0.22%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, DXR is more volatile compared to QDEL. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check QDEL's competition here
DXR vs ATRI Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, DXR is priced at $9.58, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas ATRI's P/E ratio is 64.50. In terms of profitability, DXR's ROE is +0.22%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, DXR is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check ATRI's competition here
DXR vs NNNN Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, NNNN has a market cap of 709.3M. Regarding current trading prices, DXR is priced at $9.58, while NNNN trades at $16.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas NNNN's P/E ratio is 107.73. In terms of profitability, DXR's ROE is +0.22%, compared to NNNN's ROE of +0.23%. Regarding short-term risk, DXR is more volatile compared to NNNN. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check NNNN's competition here
DXR vs ANGO Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, ANGO has a market cap of 509.9M. Regarding current trading prices, DXR is priced at $9.58, while ANGO trades at $12.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas ANGO's P/E ratio is -16.24. In terms of profitability, DXR's ROE is +0.22%, compared to ANGO's ROE of -0.18%. Regarding short-term risk, DXR is more volatile compared to ANGO. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check ANGO's competition here
DXR vs OSUR Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, OSUR has a market cap of 291.9M. Regarding current trading prices, DXR is priced at $9.58, while OSUR trades at $4.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas OSUR's P/E ratio is -4.04. In terms of profitability, DXR's ROE is +0.22%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, DXR is more volatile compared to OSUR. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check OSUR's competition here
DXR vs UTMD Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, UTMD has a market cap of 216.7M. Regarding current trading prices, DXR is priced at $9.58, while UTMD trades at $68.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas UTMD's P/E ratio is 20.14. In terms of profitability, DXR's ROE is +0.22%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, DXR is more volatile compared to UTMD. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check UTMD's competition here
DXR vs SMTI Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, SMTI has a market cap of 208.2M. Regarding current trading prices, DXR is priced at $9.58, while SMTI trades at $23.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas SMTI's P/E ratio is 378.67. In terms of profitability, DXR's ROE is +0.22%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, DXR is more volatile compared to SMTI. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check SMTI's competition here
DXR vs PDEX Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, PDEX has a market cap of 207.5M. Regarding current trading prices, DXR is priced at $9.58, while PDEX trades at $64.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas PDEX's P/E ratio is 17.91. In terms of profitability, DXR's ROE is +0.22%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, DXR is more volatile compared to PDEX. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check PDEX's competition here
DXR vs KRMD Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, KRMD has a market cap of 183.7M. Regarding current trading prices, DXR is priced at $9.58, while KRMD trades at $4.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas KRMD's P/E ratio is -80.00. In terms of profitability, DXR's ROE is +0.22%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, DXR is more volatile compared to KRMD. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check KRMD's competition here
DXR vs INFU Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, INFU has a market cap of 181.5M. Regarding current trading prices, DXR is priced at $9.58, while INFU trades at $8.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas INFU's P/E ratio is 24.31. In terms of profitability, DXR's ROE is +0.22%, compared to INFU's ROE of +0.14%. Regarding short-term risk, DXR is more volatile compared to INFU. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check INFU's competition here
DXR vs STXS Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, STXS has a market cap of 179.8M. Regarding current trading prices, DXR is priced at $9.58, while STXS trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas STXS's P/E ratio is -7.67. In terms of profitability, DXR's ROE is +0.22%, compared to STXS's ROE of -1.53%. Regarding short-term risk, DXR is more volatile compared to STXS. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check STXS's competition here
DXR vs MBOT Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, MBOT has a market cap of 82.9M. Regarding current trading prices, DXR is priced at $9.58, while MBOT trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas MBOT's P/E ratio is -7.00. In terms of profitability, DXR's ROE is +0.22%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, DXR is more volatile compared to MBOT. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check MBOT's competition here
DXR vs AKYA Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, DXR is priced at $9.58, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas AKYA's P/E ratio is -1.34. In terms of profitability, DXR's ROE is +0.22%, compared to AKYA's ROE of -27.96%. Regarding short-term risk, DXR is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check AKYA's competition here
DXR vs OMIC Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, DXR is priced at $9.58, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas OMIC's P/E ratio is -0.58. In terms of profitability, DXR's ROE is +0.22%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, DXR is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check OMIC's competition here
DXR vs IGAP Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, DXR is priced at $9.58, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas IGAP's P/E ratio is -10.52. In terms of profitability, DXR's ROE is +0.22%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, DXR is more volatile compared to IGAP. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check IGAP's competition here
DXR vs ZTEK Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, ZTEK has a market cap of 50.1M. Regarding current trading prices, DXR is priced at $9.58, while ZTEK trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas ZTEK's P/E ratio is -7.76. In terms of profitability, DXR's ROE is +0.22%, compared to ZTEK's ROE of -0.61%. Regarding short-term risk, DXR is more volatile compared to ZTEK. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check ZTEK's competition here
DXR vs NYXH Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, NYXH has a market cap of 50M. Regarding current trading prices, DXR is priced at $9.58, while NYXH trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas NYXH's P/E ratio is -0.54. In terms of profitability, DXR's ROE is +0.22%, compared to NYXH's ROE of -1.64%. Regarding short-term risk, DXR is less volatile compared to NYXH. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check NYXH's competition here
DXR vs STSS Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, STSS has a market cap of 49.1M. Regarding current trading prices, DXR is priced at $9.58, while STSS trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas STSS's P/E ratio is -0.02. In terms of profitability, DXR's ROE is +0.22%, compared to STSS's ROE of -1.66%. Regarding short-term risk, DXR is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check STSS's competition here
DXR vs POCI Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, POCI has a market cap of 43.9M. Regarding current trading prices, DXR is priced at $9.58, while POCI trades at $5.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas POCI's P/E ratio is -8.87. In terms of profitability, DXR's ROE is +0.22%, compared to POCI's ROE of -0.37%. Regarding short-term risk, DXR is more volatile compared to POCI. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check POCI's competition here
DXR vs NEPH Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, NEPH has a market cap of 35.3M. Regarding current trading prices, DXR is priced at $9.58, while NEPH trades at $3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas NEPH's P/E ratio is 46.43. In terms of profitability, DXR's ROE is +0.22%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, DXR is more volatile compared to NEPH. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check NEPH's competition here
DXR vs MLSS Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, MLSS has a market cap of 33.8M. Regarding current trading prices, DXR is priced at $9.58, while MLSS trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas MLSS's P/E ratio is -6.40. In terms of profitability, DXR's ROE is +0.22%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, DXR is less volatile compared to MLSS. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check MLSS's competition here
DXR vs SDC Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, DXR is priced at $9.58, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas SDC's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.22%, compared to SDC's ROE of -1.96%. Regarding short-term risk, DXR is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check SDC's competition here
DXR vs EKSO Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, EKSO has a market cap of 28.6M. Regarding current trading prices, DXR is priced at $9.58, while EKSO trades at $11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas EKSO's P/E ratio is -2.31. In terms of profitability, DXR's ROE is +0.22%, compared to EKSO's ROE of -1.77%. Regarding short-term risk, DXR is more volatile compared to EKSO. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check EKSO's competition here
DXR vs HBIO Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, HBIO has a market cap of 27.2M. Regarding current trading prices, DXR is priced at $9.58, while HBIO trades at $6.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas HBIO's P/E ratio is -2.81. In terms of profitability, DXR's ROE is +0.22%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, DXR is more volatile compared to HBIO. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check HBIO's competition here
DXR vs IVC Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, DXR is priced at $9.58, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas IVC's P/E ratio is -0.79. In terms of profitability, DXR's ROE is +0.22%, compared to IVC's ROE of -0.46%. Regarding short-term risk, DXR is more volatile compared to IVC. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check IVC's competition here
DXR vs RVP Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, RVP has a market cap of 20.5M. Regarding current trading prices, DXR is priced at $9.58, while RVP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas RVP's P/E ratio is -3.11. In terms of profitability, DXR's ROE is +0.22%, compared to RVP's ROE of -0.08%. Regarding short-term risk, DXR is more volatile compared to RVP. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check RVP's competition here
DXR vs FEMY Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, FEMY has a market cap of 18.5M. Regarding current trading prices, DXR is priced at $9.58, while FEMY trades at $5.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas FEMY's P/E ratio is -1.09. In terms of profitability, DXR's ROE is +0.22%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, DXR is more volatile compared to FEMY. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check FEMY's competition here
DXR vs ZJYL Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, ZJYL has a market cap of 17.9M. Regarding current trading prices, DXR is priced at $9.58, while ZJYL trades at $2.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas ZJYL's P/E ratio is 11.45. In terms of profitability, DXR's ROE is +0.22%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, DXR is more volatile compared to ZJYL. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check ZJYL's competition here
DXR vs ARTC Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, ARTC has a market cap of 16.1M. Regarding current trading prices, DXR is priced at $9.58, while ARTC trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas ARTC's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.22%, compared to ARTC's ROE of N/A. Regarding short-term risk, DXR is more volatile compared to ARTC. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check ARTC's competition here
DXR vs RGNT Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, RGNT has a market cap of 9.5M. Regarding current trading prices, DXR is priced at $9.58, while RGNT trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas RGNT's P/E ratio is -0.10. In terms of profitability, DXR's ROE is +0.22%, compared to RGNT's ROE of N/A. Regarding short-term risk, DXR is less volatile compared to RGNT. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check RGNT's competition here
DXR vs NXGL Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, NXGL has a market cap of 5.5M. Regarding current trading prices, DXR is priced at $9.58, while NXGL trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas NXGL's P/E ratio is -1.49. In terms of profitability, DXR's ROE is +0.22%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, DXR is more volatile compared to NXGL. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check NXGL's competition here
DXR vs NSTG Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, DXR is priced at $9.58, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas NSTG's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.22%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, DXR is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check NSTG's competition here
DXR vs LUCY Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, LUCY has a market cap of 3.6M. Regarding current trading prices, DXR is priced at $9.58, while LUCY trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas LUCY's P/E ratio is -0.58. In terms of profitability, DXR's ROE is +0.22%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, DXR is more volatile compared to LUCY. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check LUCY's competition here
DXR vs POAI Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, DXR is priced at $9.58, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas POAI's P/E ratio is -0.03. In terms of profitability, DXR's ROE is +0.22%, compared to POAI's ROE of -107.05%. Regarding short-term risk, DXR is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check POAI's competition here
DXR vs MHUA Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, DXR is priced at $9.58, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas MHUA's P/E ratio is 0.25. In terms of profitability, DXR's ROE is +0.22%, compared to MHUA's ROE of +0.06%. Regarding short-term risk, DXR is more volatile compared to MHUA. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check MHUA's competition here
DXR vs NXGLW Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, NXGLW has a market cap of 2M. Regarding current trading prices, DXR is priced at $9.58, while NXGLW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas NXGLW's P/E ratio is -0.02. In terms of profitability, DXR's ROE is +0.22%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, DXR is less volatile compared to NXGLW. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check NXGLW's competition here
DXR vs GMVD Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, DXR is priced at $9.58, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas GMVD's P/E ratio is -0.01. In terms of profitability, DXR's ROE is +0.22%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, DXR is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check GMVD's competition here
DXR vs GMVDW Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, DXR is priced at $9.58, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas GMVDW's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.22%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, DXR is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check GMVDW's competition here
DXR vs AVGR Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, DXR is priced at $9.58, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas AVGR's P/E ratio is -0.05. In terms of profitability, DXR's ROE is +0.22%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, DXR is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check AVGR's competition here
DXR vs STSSW Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, STSSW has a market cap of 887.9K. Regarding current trading prices, DXR is priced at $9.58, while STSSW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas STSSW's P/E ratio is -0.04. In terms of profitability, DXR's ROE is +0.22%, compared to STSSW's ROE of +0.12%. Regarding short-term risk, DXR is less volatile compared to STSSW. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check STSSW's competition here
DXR vs LUCYW Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, DXR is priced at $9.58, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas LUCYW's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.22%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, DXR is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check LUCYW's competition here
DXR vs GCTK Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, GCTK has a market cap of 293.7K. Regarding current trading prices, DXR is priced at $9.58, while GCTK trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas GCTK's P/E ratio is 0.08. In terms of profitability, DXR's ROE is +0.22%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, DXR is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for DXR.Check GCTK's competition here
DXR vs WOK Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, WOK has a market cap of 573. Regarding current trading prices, DXR is priced at $9.58, while WOK trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas WOK's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.22%, compared to WOK's ROE of -0.07%. Regarding short-term risk, DXR is more volatile compared to WOK. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check WOK's competition here
DXR vs APR Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, APR has a market cap of 0. Regarding current trading prices, DXR is priced at $9.58, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas APR's P/E ratio is 22.59. In terms of profitability, DXR's ROE is +0.22%, compared to APR's ROE of +9.81%. Regarding short-term risk, DXR is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check APR's competition here
DXR vs IVTY Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, DXR is priced at $9.58, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas IVTY's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.22%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, DXR is more volatile compared to IVTY. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check IVTY's competition here
DXR vs ATRS Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, DXR is priced at $9.58, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas ATRS's P/E ratio is 14.95. In terms of profitability, DXR's ROE is +0.22%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, DXR is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check ATRS's competition here
DXR vs HRC Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, HRC has a market cap of 0. Regarding current trading prices, DXR is priced at $9.58, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas HRC's P/E ratio is 41.92. In terms of profitability, DXR's ROE is +0.22%, compared to HRC's ROE of +0.14%. Regarding short-term risk, DXR is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check HRC's competition here
DXR vs IIN Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, IIN has a market cap of 0. Regarding current trading prices, DXR is priced at $9.58, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas IIN's P/E ratio is 226.45. In terms of profitability, DXR's ROE is +0.22%, compared to IIN's ROE of -0.00%. Regarding short-term risk, DXR is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check IIN's competition here
DXR vs ALOG Comparison June 2026
DXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXR stands at 51M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, DXR is priced at $9.58, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXR currently has a P/E ratio of 6.18, whereas ALOG's P/E ratio is N/A. In terms of profitability, DXR's ROE is +0.22%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, DXR is more volatile compared to ALOG. This indicates potentially higher risk in terms of short-term price fluctuations for DXR.Check ALOG's competition here